Eucardia has successfully closed a new capital increase, subscribed by private investors.
Marco Bottaro, CEO of Eucardia, declares: «The transaction completed today is the result of a wonderful teamwork and of the enthusiasm of the new members. It marks a turning point in Eucardia’s growth path. Thanks to this capital increase, and to the recent victory of the Marzotto Award, we can rapidly proceed to the pre-clinical validation of our device».
The operation was conducted by the Eucardia team with the precious support of Be-come srl, an innovative firm that designs high-profile solutions for innovators and changemakers. Be-come, in particular Massimiliano D’Amico and Michela Borin, coordinated the transaction from the legal and arrangement point of view.
The new funding will be used to consolidate the team and to target important goals: thanks to a protocol on animal testing and other ongoing experiments, the company expects to complete the proof-of-evidence phase and to approach the pre-clinical phase in 2018.
«The interest shown on Eucardia confirms that the life-science market can attract large private investments in Italy» added Emanuele Ottina, Head of Finance and Fund Raising of Eucardia, «a great news for innovators made in Italy and a good starting point for the next funding round».